Emibetuzumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Emibetuzumab is a bivalent antibody that blocks HGF- and MET-receptor interaction, leading to MET internalization and degradation.

Clinical Use

A phase I study determined a tolerable dose for emibetuzumab to be 700–2000 mg as a monotherapy and in combination with erlotinib in NSCLC patients. It is currently being investigated in phase II in combination with erlotinib.

Emibetuzumab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Emibetuzumab Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Aladdin Scientific		tp@aladdinsci.com	United States	57505	58
Shanghai YuanYe Biotechnology Co., Ltd.	021-61312847; 18021002903	3008007409@qq.com	China	71826	60
ShangHai Biochempartner Co.,Ltd	177-54423994 17754423994	2853530910@QQ.com	China	7990	62
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1566	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10308	58
TargetMol Chemicals Inc.	4008200310	marketing@tsbiochem.com	China	24958	58
Biolab Reagents	18108604356 18108604356	info@biolabreagent.com	China	9868	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 086-15871494362 13720134139	orders@jknbiochem.com	China	6197	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11973	58
Shanghai Aladdin Biochemical Technology Co.,Ltd.	400-6206333 13167063860	anhua.mao@aladdin-e.com	China	48458	58

---

• Emibetuzumab
• Research Grade Emibetuzumab(DHC34201)
• Emibetuzumab (anti-MET)
• LY2875358
• Research Grade Emibetuzumab
• 1365287-97-3